Our study is, to our knowledge, the first to assess the diagnostic accuracy (sensitivity and specificity) of B7-H3 immunoreactivity for differentiating high- from low-grade glioma, and it further demonstrates that elevated B7-H3 expression correlates with higher tumor grade and poorer clinical outcomes (reduced OS and PFS). The gene discussed is CD276; the disease is central nervous system cancer.